Hospital
Davis Hospital & Medical Center LP
Davis Hospital & Medical Center LP was paid $22.49M by Medicaid between Jan 2018 and Nov 2023, across 209 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 71% of everything it billed.
33Billing provider infoDAVIS HOSPITAL & MEDICAL CENTER LP
LAYTON, UT 84041
LAYTON, UT 84041
33aNPI1548205818assigned 06/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$22.49M
24GClaims417,491
24DCodes billed209
24AFirst – last monthJan 2018 – Nov 2023
Compared with peers
Next to other General Acute Care Hospital providers in Utah
Rank by total paid#3 of 26
Median peer was paid$6.14M
This provider vs. median3.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 80,508 | $3.78M | |
| 2019 | 77,129 | $3.58M | |
| 2020 | 73,985 | $4.35M | |
| 2021 | 96,343 | $5.56M | |
| 2022 | 84,739 | $5.02M | |
| 2023 | 4,787 | $195K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 71% | 59,028 | 19,982 | $15.87M |
| 36415 | Collection of venous blood by venipuncture | 14% | 27,979 | 21,621 | $3.26M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.9% | 14,305 | 12,777 | $432K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.2% | 1,613 | 1,465 | $269K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 414 | 352 | $198K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,018 | 3,404 | $184K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | <1% | 14,210 | 12,333 | $171K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,487 | 2,321 | $126K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,601 | 2,331 | $111K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,933 | 9,097 | $100K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 10,672 | 9,044 | $84K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,468 | 2,277 | $81K |
197 more codes
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 802 | $80K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,013 | $69K |
| 87400 | <1% | 1,103 | $66K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,960 | $61K |
| 81001 | <1% | 8,054 | $60K | |
| 81003 | <1% | 5,088 | $58K | |
| 82962 | <1% | 2,093 | $54K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,019 | $51K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,145 | $50K |
| 87070 | <1% | 1,065 | $47K | |
| 73610 | <1% | 539 | $44K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 684 | $38K |
| 73630 | <1% | 652 | $37K | |
| 87081 | <1% | 1,166 | $34K | |
| 73562 | <1% | 441 | $33K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 479 | $33K |
| 80053 | Comprehensive metabolic panel | <1% | 16,819 | $32K |
| 84703 | <1% | 4,633 | $31K | |
| 73110 | <1% | 340 | $30K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,981 | $29K |
| 73130 | <1% | 303 | $25K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,994 | $24K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,673 | $21K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 576 | $21K |
| 31720 | <1% | 765 | $20K | |
| 89220 | <1% | 375 | $20K | |
| 87088 | <1% | 2,117 | $19K | |
| 87486 | <1% | 524 | $19K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,014 | $19K |
| 12001 | <1% | 281 | $18K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,585 | $16K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,225 | $15K |
| C1758 | Catheter, ureteral | <1% | 621 | $14K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,824 | $14K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,469 | $14K |
| 80050 | General health panel | <1% | 2,642 | $14K |
| 87077 | <1% | 1,815 | $13K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,746 | $12K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,929 | $12K |
| 82947 | <1% | 320 | $11K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 146 | $11K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 433 | $11K |
| 73030 | <1% | 173 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,884 | $10K |
| 72100 | <1% | 139 | $10K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 360 | $10K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 28 | $10K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,381 | $9K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,740 | $9K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,377 | $9K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 720 | $9K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 98 | $8K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 608 | $8K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,956 | $8K |
| 99152 | <1% | 1,028 | $8K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,503 | $8K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,282 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,956 | $8K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,454 | $7K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 697 | $7K |
| 80081 | <1% | 184 | $6K | |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 142 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 359 | $6K |
| 83690 | <1% | 5,992 | $5K | |
| 86850 | <1% | 1,361 | $5K | |
| 81025 | <1% | 1,326 | $5K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 194 | $4K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,522 | $4K |
| 59025 | Fetal non-stress test | <1% | 994 | $4K |
| 86592 | <1% | 834 | $4K | |
| 84484 | <1% | 5,120 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,196 | $3K |
| 12011 | <1% | 55 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,613 | $3K |
| 87480 | <1% | 63 | $3K | |
| 87420 | <1% | 250 | $3K | |
| 93971 | <1% | 125 | $3K | |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 209 | $3K |
| 84702 | <1% | 1,275 | $3K | |
| C1769 | Guide wire | <1% | 34 | $3K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 233 | $3K |
| 85379 | <1% | 1,119 | $2K | |
| 86900 | <1% | 1,528 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 75 | $2K |
| 80329 | <1% | 860 | $2K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 816 | $2K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 308 | $2K |
| 74018 | <1% | 43 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,578 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,195 | $2K |
| 96376 | <1% | 1,519 | $2K | |
| 80320 | <1% | 1,101 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 341 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,742 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,548 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,697 | $1K |
| 94760 | <1% | 1,355 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,528 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 206 | $1K |
| 85610 | <1% | 1,467 | $1K | |
| J3490 | Unclassified drugs | <1% | 306 | $1K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 179 | $1K |
| 0064U | <1% | 73 | $1K | |
| 80061 | Lipid panel | <1% | 1,362 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 15 | $1K |
| 97161 | <1% | 411 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 725 | $1K |
| 86140 | <1% | 749 | $1K | |
| 87807 | <1% | 98 | $1K | |
| 82805 | <1% | 47 | $1K | |
| 73080 | <1% | 13 | $1K | |
| A9270 | Non-covered item or service | <1% | 7,582 | $952.28 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,081 | $897.72 |
| 82550 | <1% | 1,009 | $859.94 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 684 | $833.85 |
| J2704 | Injection, propofol, 10 mg | <1% | 4,658 | $722.02 |
| 84439 | <1% | 1,200 | $721.04 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 939 | $692.77 |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 49 | $643.24 |
| G0378 | Hospital observation service, per hour | <1% | 909 | $629.03 |
| 80055 | <1% | 34 | $628.95 | |
| 83880 | <1% | 1,912 | $609.30 | |
| 76801 | <1% | 59 | $519.24 | |
| 82803 | <1% | 16 | $501.48 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,319 | $485.18 |
| 90714 | <1% | 167 | $474.57 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 283 | $450.94 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 33 | $418.48 |
| 83605 | <1% | 1,330 | $407.24 | |
| 87205 | <1% | 1,039 | $400.36 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 214 | $388.39 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,856 | $387.60 |
| 87581 | <1% | 214 | $384.80 | |
| 87186 | <1% | 2,028 | $358.61 | |
| 74022 | <1% | 16 | $346.17 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 234 | $343.21 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 52 | $341.05 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 668 | $314.79 |
| 99153 | Mod sedat endo service >5yrs | <1% | 723 | $310.48 |
| 85027 | <1% | 1,513 | $235.63 | |
| G0237 | Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring) | <1% | 86 | $206.19 |
| 86403 | <1% | 24 | $173.24 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,544 | $136.03 |
| 86762 | <1% | 281 | $117.52 | |
| 86593 | <1% | 22 | $104.85 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,407 | $96.88 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 124 | $91.17 |
| 87340 | <1% | 629 | $89.06 | |
| 85007 | <1% | 681 | $77.50 | |
| 87040 | <1% | 934 | $67.01 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 113 | $52.04 |
| 87653 | <1% | 104 | $51.51 | |
| 83735 | <1% | 546 | $48.73 | |
| 80179 | <1% | 454 | $24.55 | |
| 80143 | <1% | 471 | $24.55 | |
| 82077 | <1% | 542 | $23.42 | |
| 94664 | <1% | 77 | $22.91 | |
| 86901 | <1% | 1,542 | $21.22 | |
| 86780 | <1% | 281 | $12.36 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 142 | $10.90 |
| 29125 | <1% | 16 | $10.90 | |
| 85730 | <1% | 258 | $10.50 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 89 | $6.63 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 115 | $1.90 |
| 85651 | <1% | 110 | $1.90 | |
| 80159 | 0% | 179 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 479 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 282 | $0.00 |
| 88313 | 0% | 276 | $0.00 | |
| 87260 | 0% | 38 | $0.00 | |
| 87660 | 0% | 63 | $0.00 | |
| 86703 | 0% | 22 | $0.00 | |
| A4649 | Surgical supply; miscellaneous | 0% | 233 | $0.00 |
| 83525 | 0% | 16 | $0.00 | |
| 84466 | 0% | 13 | $0.00 | |
| 86787 | 0% | 64 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 104 | $0.00 |
| 93976 | 0% | 70 | $0.00 | |
| 83540 | 0% | 13 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 29 | $0.00 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 0% | 22 | $0.00 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 0% | 13 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 624 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 473 | $0.00 |
| 82728 | 0% | 14 | $0.00 | |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 57 | $0.00 |
| 87158 | 0% | 63 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 34 | $0.00 |
| 82607 | 0% | 29 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 60 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 14 | $0.00 |
| 87510 | 0% | 63 | $0.00 | |
| 82553 | 0% | 14 | $0.00 | |
| 88304 | 0% | 16 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 21 | $0.00 |
| 86803 | 0% | 17 | $0.00 | |
| 83001 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJENSEN, MICHAEL (HOSPITAL CEO)
| Provider | Location | Paid |
|---|---|---|
| Utah Navajo Health System, Incorporated | Montezuma Creek, UT | $15.67M |
| Utah Navajo Health System, Incorporated | Blanding, UT | $2.54M |
| Utah Navajo Health System, Incorporated | Monument Valley, UT | $1.79M |
| US Homemed, LLC | Manasquan, NJ | $755K |
| Utah Navajo Health System, Incorpoarted | Blanding, UT | $151K |
| Utah Navajo Health System, Incorporated | Navajo Mountain, UT | $93K |
| Frontier Physical Therapy PC | Great Falls, MT | $32K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.